Erratum to: Prevalence and factors associated with polypharmacy in older people with cancer (Support Care Cancer DOI: 10.1007/s00520-014-2171-x);Prevalence and factors associated with polypharmacy in older people with cancer

Supportive Care in Cancer

Volumn 22, Issue 7, 2014, Pages 1727-1734

  Turner, Justin P ^a,b   Shakib, Sepehr ^c   Singhal, Nimit ^d   Hogan Doran, Jonathon ^d   Prowse, Robert ^c   Johns, Sally ^c   Bell, J Simon ^a,b  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c ROYAL ADELAIDE HOSPITAL   (Australia)

^d UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Aged; Aged 80 and over; Frail elderly; Geriatric oncology; Medical oncology; Polypharmacy

Indexed keywords

AGED; ARTICLE; CANCER PATIENT; CENTER FOR EPIDEMIOLOGICAL STUDIES DEPRESSION SCALE; CHARLSON COMORBIDITY INDEX; DAILY LIFE ACTIVITY; DISTRESS SYNDROME; EXHAUSTION; FEMALE; FRAIL ELDERLY; HUMAN; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; PAIN ASSESSMENT; PHENOTYPE; PHYSICAL ACTIVITY; POLYPHARMACY; PREVALENCE; PRIORITY JOURNAL; SHORT FORM 36; VISUAL ANALOG SCALE; WEIGHT REDUCTION;

ACTIVITIES OF DAILY LIVING; AGE FACTORS; AGED; AGED, 80 AND OVER; CROSS-SECTIONAL STUDIES; DRUG INTERACTIONS; FEMALE; FRAIL ELDERLY; GERIATRIC ASSESSMENT; HUMANS; LOGISTIC MODELS; MALE; NEOPLASMS; ODDS RATIO; PAIN; POLYPHARMACY; PREVALENCE; SELF REPORT; SOUTH AUSTRALIA;

EID: 84902360775     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-014-2246-8     Document Type: Erratum

References (51)

1. Hurria A, Browner IS, Cohen HJ, Denlinger CS, deShazo M, Extermann M, Ganti AK, Holland JC, Holmes HM, Karlekar MB, Keating NL, McKoy J, Medeiros BC, Mrozek E, O'Connor T, Petersdorf SH, Rugo HS, Silliman RA, Tew WP, Walter LC, Weir AB 3rd, Wildes T (2012) Senior adult oncology. J Natl Compr Canc Netw 10(2):162-209
2. Corcoran ME (1997) Polypharmacy in the older patient with cancer. Cancer Control 4(5):419-428
3. Hurria A, Gupta S, Zauderer M, Zuckerman EL, Cohen HJ, Muss H, Rodin M, Panageas KS, Holland JC, Saltz L, Kris MG, Noy A, Gomez J, Jakubowski A, Hudis C, Kornblith AB (2005) Developing a cancer-specific geriatric assessment: a feasibility study. Cancer 104(9):1998-2005. doi: 10.1002/cncr.21422 (Pubitemid 41513186)
4. Merle L, Laroche ML, Dantoine T, Charmes JP (2005) Predicting and preventing adverse drug reactions in the very old.Drugs Aging 22(5): 375-392 (Pubitemid 41003068)
5. Balducci L, Extermann M (2000) Management of cancer in the older person: a practical approach. Oncologist 5(3):224-237 (Pubitemid 30429942)
6. Extermann M, Aapro M, Bernabei R, Cohen HJ, Droz J-P, Lichtman S, Mor V, Monfardini S, Repetto L, Sørbye L, Topinkova E (2005) Use of comprehensive geriatric assessment in older cancer patients: recommendations from the Task Force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol 55(3):241-252. doi: 10.1016/j.critrevonc.2005.06. 003 (Pubitemid 41219694)
7. Gnjidic D, Hilmer SN, Blyth FM, Naganathan V, Waite L, Seibel MJ, McLachlan AJ, Cumming RG, Handelsman DJ, Le Couteur DG (2012) Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J Clin Epidemiol 65(9):989-995. doi: 10.1016/j.jclinepi.2012.02.018
8. McLean AJ, Le Couteur DG (2004) Aging biology and geriatric clinical pharmacology. Pharmacol Rev 56(2):163-184. doi: 10.1124/pr.56.2.4 (Pubitemid 38720828)
9. Kaufman D, Kelly J, Rosenberg L, Anderson T, Mitchell A (2002) Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA 287(3):337-344 (Pubitemid 34251967)
10. Prithviraj GK, Koroukian S, Margevicius S, Berger NA, Bagai R, Owusu C (2012) Patient characteristics associated with polypharmacy and inappropriate prescribing of medications among older adults with cancer. J Geriatr Oncol 3(3):228-237. doi: 10.1016/j.jgo.2012.02.005
11. Flood KL, Carroll MB, Le CV, Brown CJ (2009) Polypharmacy in hospitalized older adult cancer patients: experience from a prospective, observational study of an oncology-acute care for elders unit. Am J Geriatr Pharmacother 7(3):151 - 158. doi: 10.1016/j. amjopharm.2009.05.002
12. Scott I, Jayathissa S (2010) Quality of drug prescribing in older patients: is there a problem and can we improve it? Intern Med J 40(1):7-18. doi: 10.1111/j.1445-5994.2009.02040.x
13. Stegemann S, Ecker F, Maio M, Kraahs P, Wohlfart R, Breitkreutz J, Zimmer A, Bar-Shalom D, Hettrich P, Broegmann B (2010) Geriatric drug therapy: neglecting the inevitable majority. Ageing Research Reviews 9(4):384-398. doi: 10.1016/j.arr.2010.04.005
14. Roughead EE, Gilbert AL, Primrose JG, Sansom LN (1998) Drug-related hospital admissions: a review of Australian studies published 1988-1996. Med J Aust 168(8):405-408 (Pubitemid 28195764)
15. Dalleur O, Spinewine A, Henrard S, Losseau C, Speybroeck N, Boland B (2012) Inappropriate prescribing and related hospital admissions in frail older persons according to the STOPP and START criteria. Drugs Aging 29(10):829-837. doi: 10.1007/s40266-012-0016-1
16. Gaugler J, Duval S, Anderson K, Kane R (2007) Predicting nursing home admission in the U.S: a meta-analysis. BMC Geriatr 7(1):13
17. Lazarou J, Pomeranz BH, Corey PN (1998) Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279(15):1200-1205. doi: 10.1001/jama.279.15.1200 (Pubitemid 28193431)
18. Jorgensen T, Herrstedt J, Friis S, Hallas J (2012) Polypharmacy and drug use in elderly Danish cancer patients during 1996 to 2006. J Geriatr Oncol 3(1):33-40
19. Puts M, Costa-Lima B, Monette J, Girre V, Wolfson C, Baptist G, Bergman H (2009) Medication problems in older, newly diagnosed cancer patients in Canada: how common are they? A prospective pilot study. Drugs Aging 26(6):519-536
20. Tam-McDevitt J (2008) Polypharmacy, aging, and cancer. Oncology 22(9):1052-1055
21. Todd A, Williamson S, Husband A, Baqir W, Mahony M (2012) Patients with advanced lung cancer: is there scope to discontinue inappropriate medication? Int J Clin Pharm. doi: 10.1007/s11096-012-9731-2
22. Riechelmann RP, Moreira F, Smaletz O, Saad ED (2005) Potential for drug interactions in hospitalized cancer patients. Cancer Chemother Pharmacol 56(3):286-290. doi: 10.1007/s00280-004-0998-4 (Pubitemid 40941799)
23. Lees J, Chan A (2011) Polypharmacy in elderly patients with cancer: clinical implications and management. Lancet Oncol 12(13):1249-1257. doi: 10.1016/S1470-2045(11)70040-7
24. To T, Okera M, Prouse J, Prowse R, Singhal N (2010) Infancy of an Australian geriatric oncology program - characteristics of the first 200 patients. J Geriatr Oncol 1(2):81-86
25. Roth AJ, Kornblith AB, Batel-Copel L, Peabody E, Scher HI, Holland JC (1998) Rapid screening for psychologic distress in men with prostate carcinoma: a pilot study. Cancer 82(10):1904-1908. doi: 10.1002/(SICI)1097-0142(19980515) 82:10<1904::AIDCNCR13>3.0.CO;2-X (Pubitemid 28208646)
26. Fillenbaum GG, Smyer MA (1981) The development, validity, and reliability of the OARS multidimensional functional assessment questionnaire. J Gerontol 36(4):428-434 (Pubitemid 11070078)
27. Karnofsky DA, Burchenal JH (1949) The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod CM (ed) Evaluation of chemotherapeutic agents. Columbia University Press, New York, p 196
28. Ware JE Jr, Sherbourne CD (1992) The MOS 36-item Short-Form Health Survey (SF-36): I. Conceptual framework and item selection. Med Care 30:473-483
29. Orme JG, Reis J, Herz EJ (1986) Factorial and discriminant validity of the Center for Epidemiological Studies Depression (CES-D) Scale. J Clin Psychol 42(1):28-33 (Pubitemid 16188206)
30. Fried LP, Tangen CM,Walston J, Newman AB, Hirsch C, Gottdiener J, Seeman T, Tracy R, Kop WJ, Burke G, McBurnie MA, Cardiovascular Health Study Collaborative Research Group (2001) Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 56(3):M146-156 (Pubitemid 32187141)
31. Lees J, Toh B (2009) Does a pharmacist derived medication history (MH) provide more information than a geriatric cancer patient-completed medication list, and does it matter? Asia-Pac J Clin Oncol 5(Suppl 2):A176
32. Lau HS, Florax C, Porsius AJ, De Boer A (2001) The completeness of medication histories in hospital medical records of patients admitted to general internal medicine wards. Br J Clin Pharmacol 49(6):597-603 (Pubitemid 30326560)
33. WHO Collaborating Centre for Drug Statistics Methodology (2011) Guidelines for ATC classification and DDD assignment, 2012
34. Gnjidic D, Hilmer SN, Blyth FM, Naganathan V, Cumming RG, Handelsman DJ, McLachlan AJ, Abernethy DR, Banks E, Le Couteur DG (2012) High-risk prescribing and incidence of frailty among older community-dwelling men. Clin Pharmacol Ther 91(3):521-528. doi: 10.1038/clpt.2011.258
35. Pal SK, Katheria V, Hurria A (2010) Evaluating the older patient with cancer: understanding frailty and the geriatric assessment. CA Cancer J Clin 60(2):120-132. doi: 10.3322/caac.20059
36. Decoster L, Kenis C, Van Puyvelde K, Flamaing J, Conings G, De Greve J, Mets T, Milisen K, Lobelle JP, Wildiers H (2013) The influence of clinical assessment (including age) and geriatric assessment on treatment decisions in older patients with cancer. J Geriatr Oncol 4(3):235-241. doi: 10.1016/j.jgo.2013.04.010
37. Fusco O, Ferrini A, Santoro M, Lo Monaco MR, Gambassi G, Cesari M (2012) Physical function and perceived quality of life in older persons. Aging Clin Exp Res 24(1):68-73
38. Covinsky KE, Hilton J, Lindquist K, Dudley RA (2006) Development and validation of an index to predict activity of daily living dependence in community-dwelling elders. Med Care 44(2):149-157 (Pubitemid 43755466)
39. Fede A, Miranda M, Antonangelo D, Trevizan L, Schaffhausser H, Hamermesz B, Zimmermann C, Del Giglio A, Riechelmann RP (2011) Use of unnecessary medications by patients with advanced cancer: cross-sectional survey. Support Care Cancer 19(9):1313-1318
40. Gnjidic D, Cumming RG, Le Couteur DG, Handelsman DJ, Naganathan V, Abernethy DR, Hilmer SN (2009) Drug burden index and physical function in older Australian men. Br J Clin Pharmacol 68(1):97-105. doi: 10.1111/j.1365-2125.2009. 03411.x
41. Kaplan GA, Strawbridge WJ, Camacho T, Cohen RD (1993) Factors associated with change in physical functioning in the elderly: a six-year prospective study. J Aging Health 5(1):140-153 (Pubitemid 23028986)
42. Scott D, Blizzard L, Fell J, Jones G (2009) Statin therapy, muscle function and falls risk in community-dwelling older adults. QJM 102(9):625-633. doi: 10.1093/qjmed/hcp093
43. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E,Domecq C,Greenblatt DJ (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30(2):239-245 (Pubitemid 12149145)
44. Payne RA, Abel GA, Avery AJ, Mercer SW, Roland MO (2014) Is polypharmacy always hazardous? A retrospective cohort analysis using linked electronic health records from primary and secondary care. Br J Clin Pharmacol. http://onlinelibrary.wiley.com/doi/10.1111/bcp.12292/abstract. Accessed 17 Jan 2014
45. Riechelmann RP, Krzyzanowska MK, Zimmermann C (2009) Futile medication use in terminally ill cancer patients. Support Care Cancer 17(6):745-748
46. Stavrou EP, Buckley N, Olivier J, Pearson SA (2012) Discontinuation of statin therapy in older people: does a cancer diagnosis make a difference? An observational cohort study using data linkage. BMJ Open 2(3)
47. Balducci L, Goetz-Parten D, Steinman MA (2013) Polypharmacy and the management of the older cancer patient. Ann Oncol 24(suppl 7):vii36-40, 10.1093/annonc/mdt266
48. Currow DC, Stevenson JP, Abernethy AP, Plummer J, Shelby-James TM (2007) Prescribing in palliative care as death approaches. J Am Geriatr Soc 55(4):590-595. doi: 10.1111/j.1532-5415.2007.01124.x (Pubitemid 46496589)
49. Turner J, Singhal N, Bell JS (2013) Opportunities for deprescribing statins in patients with poor cancer prognosis. J Palliat Med. doi: 10.1089/jpm.2013.0278
50. Frechen S, Zoeller A, Ruberg K, Voltz R, Gaertner J (2012) Drug interactions in dying patients: a retrospective analysis of hospice inpatients in Germany. Drug Saf 35(9):745-758
51. Cruz-Jentoft AJ, Boland B, Rexach L (2012) Drug therapy optimization at the end of life. Drugs Aging 29(6):511-521. doi: 10.2165/11631740-000000000- 00000